SCHEMBL3884472

SCHEMBL3884472

Cc1ccc(NC(=O)Nc2ccc(-c3c(C(N)=O)[nH]c4ccccc34)cc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2 P11137 5/20 0.63
KDR P35968 6/20 0.57
PDGFRB P09619 5/20 0.57
STING1 Q86WV6 1/20 0.52
GSK3B P49841 1/20 0.50
ADK P55263 1/20 0.50
GAA P10253 1/20 0.49
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 2/20 0.48
KMT2A Q03164 2/20 0.47
ADORA3 P0DMS8 1/20 0.46
RAB9A P51151 1/20 0.46
KIT P10721 1/20 0.46
FLT3 P36888 1/20 0.46
PTGS2 P35354 1/20 0.45
MEN1 O00255 1/20 0.45
HTT P42858 1/20 0.45
GFER P55789 1/20 0.45
HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3883071 0.92 KDR (0.60) MAP2KDRPDGFRBSTING1GAA
SCHEMBL3879170 0.91 MAP2 (0.72) MAP2KDRPDGFRBGSK3BGAA
SCHEMBL3879349 0.90 KDR (0.73) MAP2KDRPDGFRBGSK3BGAA
SCHEMBL3883640 0.88 MAP2 (0.63) MAP2KDRPDGFRBSTING1GAA
SCHEMBL3879403 0.88 MAP2 (0.63) MAP2KDRPDGFRBSTING1GAA
SCHEMBL3877984 0.88 KDR (0.75) MAP2KDRPDGFRBRAB9AKIT
SCHEMBL3877576 0.87 MAP2 (0.59) MAP2KDRPDGFRBSTING1GAA
SCHEMBL3880397 0.87 MAP2 (0.59) MAP2KDRPDGFRBGAAKDM4E
SCHEMBL3888326 0.87 MAP2 (0.59) MAP2KDRPDGFRBGAAKDM4E
SCHEMBL3888349 0.87 MAP2 (0.59) MAP2KDRPDGFRBGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7566736-B2 Substituted indoles, compositions containing them, method for the production thereof and their use AVENTIS PHARMA S.A. (FR) 2009-07-28 US claimed
US-20070259910-A1 Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use AVENTIS PHARMA S.A. (FR) 2007-11-08 US claimed
EP-1841762-A1 SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE Aventis Pharma S.A. (FR) 2007-10-10 EP claimed
WO-2006061493-A1 SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AVENTIS PHARMA S.A. (FR) 2006-06-15 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259910-A1 Substituted Indoles, Compositions Containing Them, Method for the Production Thereof and Their Use IDO1, RB1, IDO2 MAP2 1170/4885KDR 1690/4885PDGFRB 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.